Breaking News Instant updates and real-time market news.

HOLX

Hologic

$42.78

0.46 (1.09%)

, JAZZ

Jazz Pharmaceuticals

$138.82

1.93 (1.41%)

04:55
03/16/17
03/16
04:55
03/16/17
04:55

Barclays to hold a conference

Global Healthcare Conference is being held in Miami Beach, FL on March 14-16.

HOLX

Hologic

$42.78

0.46 (1.09%)

JAZZ

Jazz Pharmaceuticals

$138.82

1.93 (1.41%)

KND

Kindred Healthcare

$8.25

0.15 (1.85%)

JNJ

Johnson & Johnson

$128.96

1.91 (1.50%)

IART

Integra LifeSciences

$43.26

0.23 (0.53%)

WCG

WellCare

$144.25

4.23 (3.02%)

BAX

Baxter

$52.16

0.26 (0.50%)

ALNY

Alnylam

$54.27

2.74 (5.32%)

TMO

Thermo Fisher

$161.05

2.71 (1.71%)

BLU

Blue Chip Value Fund, Inc.

ARA

American Renal Associates

$17.38

-0.29 (-1.64%)

ABBV

AbbVie

$66.55

0.88 (1.34%)

CVS

CVS Health

$79.73

-0.16 (-0.20%)

CNC

Centene

$68.56

1.06 (1.57%)

ESRX

Express Scripts

$66.06

-0.78 (-1.17%)

CHRS

Coherus Biosciences

$22.50

0.325 (1.47%)

ONCE

Spark Therapeutics

$59.50

0.59 (1.00%)

HALO

Halozyme

$13.86

0.55 (4.13%)

UHS

Universal Health

$121.47

1.42 (1.18%)

MMSI

Merit Medical

NK

NantKwest

$3.81

0.25 (7.02%)

DXCM

Dexcom

$77.21

-0.26 (-0.34%)

  • 16

    Mar

  • 16

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 09

    Jun

HOLX Hologic
$42.78

0.46 (1.09%)

03/13/17
JEFF
03/13/17
NO CHANGE
Target $49
JEFF
Buy
Jefferies sees inflection for 3D mammography, ups Hologic target
Jefferies analyst Raj Denhoy raised his price target for Hologic to $49 from $46 saying adoption of 3D mammography "appears to be on the cusp of an inflection." In the conversion from analog to 2D digital, growth accelerated dramatically in year seven, which is where we are in the 3D cycle, Denhoy tells investors in a research note. He adds that his firm's survey of 25 hospitals suggests that 3D penetration will continue with Hologic the main beneficiary. Denhoy keeps a Buy rating on the shares.
02/16/17
JPMS
02/16/17
INITIATION
Target $56.5
JPMS
Neutral
ZELTIQ reinstated with a Neutral at JPMorgan
JPMorgan analyst Tycho Peterson reinstated ZELTIQ Aesthetics (ZLTQ) with a Neutral rating and $56.50 price target following a period of restriction. The analyst does not expect a competing takeover bid to Allergan's (AGN) to emerge, especially with Hologic (HOLX) recently acquiring Cynosure (CYNO).
02/21/17
PIPR
02/21/17
NO CHANGE
Target $51
PIPR
Overweight
Piper ups Hologic target to $51 after management meetings
Piper Jaffray analyst William Quirk raised his price target for Hologic to $51 from $48 saying management in recent meetings was bullish on the potential selling synergies within its Ob/Gyn team and Cynosure. The analyst sees "several non-traditional channels" for products like Mona Lisa and Sculpsure. He keeps an Overweight rating on Hologic.
02/15/17
02/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fossil (FOSL) downgraded to Underperform from Market Perform at Wells Fargo, with analyst Ike Boruchow saying Q4 sales missed expectations "despite a much hyped push into wearables" while Q1 trends suggest that reorder activity has been "extremely weak following their holiday sell-in." 2. Under Armour (UA) downgraded to Negative from Neutral at Susquehanna, with analyst Sam Posner arguing that 20% annual revenue growth is "a thing of the past for the foreseeable future." Poser tells investors that commentary by CEO Kevin Plank in the current "polarized political climate" make it "nearly impossible" to effectively build a cool urban lifestyle brand, noting that several stars reacted unfavorably to his comments. 3. Hologic (HOLX) downgraded to Neutral from Buy at BofA/Merrill, with analyst Derik de Bruin saying the Cynosure (CYNO) acquisition enhances growth but at lower margins. The analyst said Cynosure adds new higher growth revenue but margins and cash flows are low relative to Hologic's and will not fully offset dilution from the recent blood screening divestiture. 4. Aircastle (AYR) downgraded to Market Perform from Outperform at Cowen by analyst Helane Becker, who said the company's growth rate is slowing as aircraft acquisition is more competitive. Aircastle was also downgraded at FBR Capital to Market Perform from Outperform. 5. Convergys (CVG) downgraded to Hold from Buy at SunTrust by analyst Frank Atkins, who said top line growth may be limited near-term due to increased uncertainty driving weakness in the demand environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
JAZZ Jazz Pharmaceuticals
$138.82

1.93 (1.41%)

02/23/17
02/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monsanto (MON) initiated with a Sector Perform at RBC Capital. 2. FMC Corporation (FMC) initiated with an Outperform at RBC Capital. 3. OncoCyte (OCX) initiated with a Buy at Chardan. 4. Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Evercore ISI. 5. Reata Pharmaceuticals (RETA) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/17
JPMS
03/13/17
NO CHANGE
Target $190
JPMS
Overweight
JPMorgan continues to see attractive entry point in Jazz
After meeting with CFO Matt Young, JPMorgan analyst Jessica Fye says Jazz Pharmaceuticals remains one of her favorite stocks. She continues to believe that current stock levels offer an attractive entry point. The analyst expects "healthy" sales and earnings growth in 2017 as well as de-risking events around JZP-110, Vyxeos and potentially JZP-507. Fye keeps an Overweight rating on Jazz with a $190 price target.
03/01/17
LEER
03/01/17
NO CHANGE
Target $170
LEER
Outperform
Jazz Pharmaceuticals price target lowered to $170 from $182 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $170 from $182 mainly due to lower Defitelio and terminal value assumptions. The analyst reiterates an Outperform rating on the shares.
03/01/17
COWN
03/01/17
NO CHANGE
Target $190
COWN
Outperform
Jazz Pharmaceuticals nearing an inflection point, says Cowen
Cowen analyst Ken Cacciatore believes Jazz Pharmaceuticals is nearing an interesting inflection point. He sees the Xyrem litigation extending the Jazz franchise to 2024/2025. With potential positive trial data coming, the shares could be nearing a complete re-rating, said Cacciatore, who reiterated his Outperform rating and $190 price targeted on Jazz shares.
KND Kindred Healthcare
$8.25

0.15 (1.85%)

11/08/16
STFL
11/08/16
DOWNGRADE
STFL
Sell
Kindred Healthcare downgraded to Sell from Hold at Stifel
11/08/16
STFL
11/08/16
DOWNGRADE
STFL
Sell
Kindred Healthcare downgraded on Q3 miss, guidance cut at Stifel
As noted earlier, Stifel downgraded Kindred to Sell from Hold. Analyst Chad Vanacore downgraded the stock based on the company's weaker than expected results and guidance reduction. Target to $5 from $10.
11/10/16
RBCM
11/10/16
DOWNGRADE
RBCM
Sector Perform
Kindred Healthcare downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Frank Morgan downgraded Kindred after the company lowered its fiscal 2016 guidance. Morgan says that the guidance cut was caused by pressures on the company's SNF segment. Morgan adds that the company's planned exit from its SNF business, along with regulatory pressures, will produce "significant uncertainties and likely bumpiness." He thinks that the stock could rebound in the near-term, but he expects it to subsequently be "range-bound" for "the next year or so." Target to $9 from $16.
JNJ Johnson & Johnson
$128.96

1.91 (1.50%)

02/16/17
OPCO
02/16/17
NO CHANGE
OPCO
Outperform
Codman acquisition strengths Integra neurosurgery position, says Oppenheimer
Following the announcement that Integra LifeSciences (IART) acquired the Codman Neurosurgery Business from Johnson & Johnson (JNJ), Oppenheimer analyst Steven Lichtman says the addition brings complementary products to further strengthen the former's position in the neurosurgery market. Additionally, the analyst notes that the deal also expands Integra LifeSciences' international revenue and adds to the company's international infrastructure that will be supportive primarily of its neurosurgery business, but will also help in the international build-out of other segments. He reiterates an Outperform rating on Integra LifeSciences' shares.
02/27/17
BERN
02/27/17
NO CHANGE
BERN
J&J executive 'most admired' Colgate-Palmolive, Reading & Bates, says Bernstein
Bernstein analyst Ali Dibadj says that Johnson & Johnson (JNJ) "made clear it has appetite" for M&A in the consumer space. According to the analyst, J&J's head of consumer says he "most admired Colgate-Palmolive (CL) and Reading & Bates (RB)."
03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
02/17/17
RBCM
02/17/17
NO CHANGE
Target $105
RBCM
Outperform
Edgewell Personal Care remains takeout target, says RBC Capital
After Kraft Heinz (KHC) confirmed it had approached Unilever (UN, UL) with a merger proposal, RBC Capital analyst Nik Modi says the news come as a surprise, but does not warrant a change in his Edgewell Personal Care (EPC) takeout thesis. The analyst reiterates an Outperform rating on the latter's shares, with a $105 price target, on improving margin and revenue profile and the prospects of a takeout in the next 12-16 months, with Unilever as one of the more likely buyers. Other potential suitors include Kimberly-Clark (KMB), Beiersdorf, Henkel, Johnson & Johnson (JNJ), Colgate-Palmolive (CL), Church & Dwight (CHD), L'Oreal (LRLCY), and Kao, he adds.
IART Integra LifeSciences
$43.26

0.23 (0.53%)

02/24/17
OPCO
02/24/17
NO CHANGE
Target $54
OPCO
Outperform
Integra LifeSciences price target raised to $54 from $48 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Integra LifeSciences to $54 from $48 following quarterly results. The analyst reiterates an Outperform rating on the shares.
02/15/17
PIPR
02/15/17
NO CHANGE
PIPR
Overweight
Integra deal accretion assumptions look conservative, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said Integra LifeSciences' (IART) acquisition of Codman Neurosurgery from Johnson & Johnson (JNJ) makes sense strategically and while cautioning that "large deals like this often have their bumps along the way" in transition, he thinks Integra has probably been conservative while properly incorporating those into their 2018 accretion estimates. He says caution is warranted during the integration period, but likes the deal longer term and keeps an Overweight rating on Integra shares.
03/06/17
UBSW
03/06/17
NO CHANGE
Target $48
UBSW
Buy
Integra LifeSciences attractive at current levels, says UBS
UBS analyst Matt Miksic met with Integra LifeSciences management and came away saying shares look attractive at current levels. The analyst said management focused on its acquisitions of Codman and Derma Sciences, which will strengthen its core positions in wound care and neurosurgery. Miksic reiterated his Buy rating and $48 price target on Integra LifeSciences shares, but noted that his target does not yet reflect the Codman deal.
WCG WellCare
$144.25

4.23 (3.02%)

01/19/17
JEFF
01/19/17
NO CHANGE
JEFF
Buy
Cigna could pursue M&A if deal breaks, says Jefferies
Jefferies analyst David Windley said a report indicating that a judge is getting set to block the merger of Anthem (ANTM) with Cigna (CI) shouldn't come as a surprise given that "dysfunction" between their management teams has been well documented. Assuming the deal is not approved, Cigna will have a strong balance sheet to repurchase stock or pursue M&A and WellCare (WCG) would be a logical takeover target, Windley contends. He also thinks Cigna could look to buy Humana (HUM) if its deal with Aetna (AET) also breaks, but acknowledges that deal would face "a much tougher road." Windley keeps his Buy rating on Cigna and Hold rating on Anthem.
01/23/17
LEER
01/23/17
NO CHANGE
Target $250
LEER
Outperform
Leerink sees Humana as target again after broken deal
After a judge sided with the Department of Justice in blocking Aetna's (AET) buyout of Humana (HUM), Leerink analyst Ana Gupte believes Humana could become a takeover target. Cigna (CI) is the most likely bidder, followed by Anthem (ANTM), Express Scripts (ESRX) and CVS Health (CVS), Gupte tells investors in a research note. The analyst expects Anthem's buyout of Cigna to also be blocked. After Humana, Gupte sees WellCare (WCG), Molina Healthcare (MOH) and Magellan Health (MGLN) as the most likely publicly traded targets post the deal breaks. She reiterates an Outperform rating on Humana with a standalone price target of $250. The stock is down 97c to $199.56 in afternoon trading.
01/26/17
PIPR
01/26/17
NO CHANGE
Target $67
PIPR
Overweight
Piper views Medicaid managed care names as undervalued
Piper Jaffray analyst Sarah James views the Medicaid focused managed care names she covers, namely Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG), as undervalued. "Rapidly" improving sentiment should drive multiple expansion over the next three months, James tells investors in a research note. She believes Medicaid managed care organizations have the ability to reach 10%-15% revenue growth through new state expansion plans and long-term service and support carve-ins. Centene is her top pick in the space with an Overweight rating and $67 price target.
02/09/17
LEER
02/09/17
NO CHANGE
Target $170
LEER
Outperform
WellCare price target raised to $170 from $160 at Leerink
Leerink analyst Ana Gupte raised her price target for WellCare (WCG) to $170 from $160 following the company's "strong" EPS beat in Q4. The analyst believes WellCare is largely insulated from the downside of the Affordable Care Act "Repeal and Replace" given it had no exposure to Public Exchanges, while its exposure to Medicaid expansion is limited. Gupte sees a takeout as likely, with Aetna (AET) as the most likely buyer followed by Cigna (CI) or Anthem (ANTM). She reiterates an Outperform rating on WellCare's shares.
BAX Baxter
$52.16

0.26 (0.50%)

09/15/16
LEHM
09/15/16
INITIATION
Target $52
LEHM
Overweight
Baxter reinstated with an Overweight at Barclays
Barclays analyst Matthew Taylor reinstated Baxter International with an Overweight rating and $52 price target. The analyst sees upside to the company's long-term growth and margin targets.
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Baxter initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Baxter International with an Outperform rating and $53-$55 price target range. The analyst sees "significant balance sheet optionality" for the company to further enhance its organic growth via acquisition and/or sizeable share repurchase programs.
06/24/16
PIPR
06/24/16
NO CHANGE
PIPR
Medical equipment makers' exposure to U.K. 'manageable,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien estimated that the direct exposure to the U.K. of the medical equipment names in the firm's coverage with the largest Euro/Pound exposure is roughly 5%, which he believes is "manageable." The names in the space with the largest Euro/Pound exposure are Dentsply Sirona (XRAY) Cooper (COO), K2M Group (KTWO), Globus Medical (GMED), ResMed (RMD), Zimmer Biomet (ZBH), Edwards Lifesciences (EW) and Baxter (BAX), said O'Brien, who added that manufacturing may help lessen the impact for Zimmer, Edwards, Baxter and Cooper.
ALNY Alnylam
$54.27

2.74 (5.32%)

02/03/17
JMPS
02/03/17
NO CHANGE
Target $69
JMPS
Outperform
Alnylam fitusiran Phase I results 'compelling,' says JMP Securities
JMP Securities analyst Michael King noted that Alnylam Pharmaceuticals presented Phase I results of fitusiran for the treatment of hemophilia A & B patients at a medical meeting in Paris that he calls "compelling." These data, combined with positive recent clinical results, continue to support the potential of fitusiran, he tells investors. King keeps an Outperform rating and $69 price target on Alnylam shares.
02/02/17
LTCO
02/02/17
INITIATION
Target $75
LTCO
Buy
Alnylam initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Christopher James started Alnylam Pharmaceuticals with a Buy rating and $75 price target.
01/09/17
CHDN
01/09/17
NO CHANGE
Target $97
CHDN
Buy
Alnylam price target raised to $97 from $69 at Chardan
Chardan analyst Madhu Kumar raised his price target for Alnylam to $97 from $69 as he sees a 60% likelihood of success for the company's phase III APOLLO trial of RNAi drug patisiran for the treatment of TTR familial amyloid polyneuropathy, the results of which are expected in late-2017. The results are critical not only for the development of patisiran, but for the broader validation of Alnylam's RNAi platform, said Kumar, who believes the company's shares are currently priced assuming failure of APOLLO, leaving risk skewed to the upside. Kumar keeps a Buy rating on Alnylam shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
TMO Thermo Fisher
$161.05

2.71 (1.71%)

12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
12/14/16
JPMS
12/14/16
DOWNGRADE
Target $6
JPMS
Neutral
Accuray downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accuray (ARAY) to Neutral citing a "sluggish" end market and the company's ongoing operational challenges. Accuray has not demonstrated consistent order growth or the ability to drive market share, Peterson tells investors in a research note. He lowered his price target for the shares to $6 from $8. The analyst's top picks in the Life Sciences space for 2017 are Agilent (A) and Thermo Fisher (TMO). Peterson this morning also downgraded Bruker (BRKR) to Underweight,
01/04/17
LEHM
01/04/17
UPGRADE
Target $51
LEHM
Overweight
Agilent upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jack Meehan upgraded Agilent Technologies (A) to Overweight saying strength in biopharma and a new gas chromatography product cycle can drive improved growth. The analyst raised his price target for the shares to $51 from $48. Meehan adds that Thermo Fisher (TMO) remains his top pick in U.S. Life Science Tools & Diagnostics. The analyst lowered his view of the sector to Neutral from Positive as he sees a more balanced set-up in the near-term.
01/18/17
DBAB
01/18/17
INITIATION
Target $163
DBAB
Buy
Thermo Fisher initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Dan Leonard started Thermo Fisher with a Buy rating and $163 price target.
BLU Blue Chip Value Fund, Inc.

ARA American Renal Associates
$17.38

-0.29 (-1.64%)

11/21/16
GSCO
11/21/16
DOWNGRADE
Target $22
GSCO
Sell
American Renal Associates downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst Matthew Borsch downgraded American Renal Associates to Sell saying the company's decision to temporarily suspend certain assistance for charitable premium support is a "key risk" to maintaining its higher pricing and previous earnings growth trajectory. The analyst sees see near-term risk to American Renal's pricing advantage. He raised his price target for the shares to $22 from $20.
03/09/17
03/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Casey's General Stores (CASY) downgraded to Neutral from Buy at Northcoast. 2. RE/MAX Holdings (RMAX) downgraded to Sell from Neutral at Compass Point. 3. American Renal Associates (ARA) downgraded to Market Perform at Wells Fargo with analyst Gary Lieberman saying the company's 2017 is uncertain. Management said there could be additional pressure on commercial contracts while the lack of EBITDA guidance is a concern, Lieberman tells investors in a research note. He lowered his price target range for the shares to $17-$19 from $22-$26. 4. Travelport (TVPT) downgraded to Neutral from Buy at UBS with analyst Eric Sheridan saying the company's near-term investments will "place a lid" on the shares. The analyst believes the stock will be "stuck in a trading range" pending greater clarity on forward revenue growth. He cut his price target for the shares to $13 from $18. 5. Virtusa (VRTU) downgraded to Hold from Buy at Maxim with analyst Brian Kinstlinger saying he believes slower industry growth and a need to invest in digital and cloud will cap margin expansion in fiscal 2018 and thinks caution is warranted ahead of the company's fiscal year guidance. He added that he expects the company's FY18 guidance to be "meaningfully" below the current consensus view. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/09/17
WELS
03/09/17
DOWNGRADE
WELS
Market Perform
American Renal Associates downgraded to Market Perform at Wells Fargo
Wells Fargo analyst Gary Lieberman downgraded American Renal Associates to Market Perform from Outperform saying the company's 2017 is uncertain. Management said there could be additional pressure on commercial contracts while the lack of EBITDA guidance is a concern, Lieberman tells investors in a research note. He lowered his price target range for the shares to $17-$19 from $22-$26.
11/14/16
RHCO
11/14/16
NO CHANGE
RHCO
American Renal weakness creates opportunity, says SunTrust
SunTrust analyst David McDonald says that American Renal reported "solid" Q3 results, and the analyst thinks that concerns related to the ACA are overdone. The analyst expects the company to continue to benefit from its "sizable development activity." He recommends buying the stock on weakness.
ABBV AbbVie
$66.55

0.88 (1.34%)

03/07/17
JEFF
03/07/17
NO CHANGE
Target $90
JEFF
Buy
Jefferies 'strongly' reiterates AbbVie as a top pick
Jefferies analyst Jeffrey Holford "strongly" reiterates AbbVie as his top pick following a "deep dive" analysis into Rova-T for small cell lung cancer. The analyst now sees even greater potential for Rova-T than consensus after raising his peak sales estimate to $4.3B with risk-adjusted revenues of $2.8B by 2025, well above the consensus of $1.8B. AbbVie's pipeline is undervalued as consensus expectations introduce U.S. Humira biosimilars too early in 2019, Holford tells investors in a research note. He keeps a Buy rating on the shares with a $90 price target. The stock closed yesterday up 22c to $63.55.
03/10/17
GSCO
03/10/17
UPGRADE
Target $80
GSCO
Conviction Buy
AbbVie upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Jami Rubin upgraded AbbVie to Conviction Buy and raised its price target to $80 from $74 saying it is one of the most compelling values across healthcare coverage, let alone US pharma. The analyst continues to believes AbbVie substantial cash flow generatin from Humira, approximately $60B over the next five years, and its diversified late stage pipeline are under-appreciated by investors.
03/10/17
03/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Yum! Brands (YUM) upgraded to Outperform on valuation at Evercore ISI with analyst Matt MCGinley saying he changed his view due to the recent pullback in shares and said there is solid visibility into multi-year earnings growth from G&A reductions and share buybacks. 2. AbbVie (ABBV) upgraded to Conviction Buy from Buy at Goldman with analyst Jami Rubin saying it is one of the most compelling values across healthcare coverage, let alone U.S. pharma. 3. Fairmount Santrol (FMSA) upgraded to Buy from Hold at Jefferies with analyst Brad Handler saying the 41% pullback in shares over the past two weeks does not reflect industry fundamentals. The analyst remains comfortable with medium term frac sand industry demand/supply fundamentals. He lowered his price target for the shares to $10 from $12. 4. Fly Leasing (FLY) upgraded to Buy from Neutral at Compass Point. 5. Camden Property (CPT) upgraded to Buy from Neutral at Goldman with analyst Andrew Rosivach citing lower supply and "sustained strong demand," particularly in Houston. The analyst raised his price target for the shares to $94 from $84. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/24/17
LEER
02/24/17
NO CHANGE
LEER
Merck write-down suggests 'rest of Idenix' is now 'very small,' says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced that it is taking a $2.9B impairment charge against the value of uprifosbuvir, or MK3682, which is the most important of the Hepatitis C nucleotide polymerase inhibitors it acquired from Idenix. The analyst believes this write-down suggests that the remaining value of the "rest of Idenix" is now very small. In addition to the delay for Merck's triple regimen, this impairment has "significant competitive implications" for Gilead (GILD) and AbbVie (ABBV), which are the most likely remaining participants in the HCV market, he adds.
CVS CVS Health
$79.73

-0.16 (-0.20%)

02/28/17
BOFA
02/28/17
NO CHANGE
BOFA
CVS Health removed from US 1 List at BofA/Merrill
02/10/17
LEER
02/10/17
NO CHANGE
Target $90
LEER
Outperform
Leerink remains positive on CVS Health following earnings
Leerink analyst David Larsen remains positive on CVS Health following earnings. The analyst believes the stock has come under "significant pressure" due to negative sentiment around transparency, Trump, DIR fees, the loss of volumes to WBA, pricing, and the new threat of Optum. However, Larsen expects sentiment to turn-around in 2017 as pricing is now fully accounted for in CVS' outlook, Trump will discover that the PBMs improve net drug trend, and PBM is having a good selling season with a high retention rate and good new wins. He reiterates an Outperform rating and $90 price target on the shares.
02/06/17
02/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AutoNation (AN) downgraded to Hold from Buy at Evercore ISI with analyst Michael Montani saying calendar year 2017 is shaping up to be an investment year and reduced estimates. The analyst said the AutoNation USA brand extension strategy means fewer franchised acquisitions and more pre-open expense for this year and next. 2. LabCorp (LH) downgraded to Neutral from Outperform at Baird with analyst Whit Mayo saying he is less convinced the company can grow earnings double digits in 2017, the current valuation is above historical averages, and he does not see an M&A deal that would meaningfully alter the risk/reward. 3. Tiffany (TIF) downgraded to Neutral from Buy at Mizuho and to Hold from Buy at HSBC. 4. CVS Health (CVS) downgraded to Neutral from Overweight at Atlantic Equities. 5. NVIDIA (NVDA) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying he "struggles" to articulate a valuation-driven for the stock meaningfully above current trading levels. Nonetheless, the analyst expects another "outstanding result" when the company announces earnings this week. He raised his price target on the shares to $120 from $95. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
JPMS
02/09/17
NO CHANGE
JPMS
CVS Health shares defended at JPMorgan
CNC Centene
$68.56

1.06 (1.57%)

02/08/17
UBSW
02/08/17
NO CHANGE
Target $80
UBSW
Buy
Centene price target raised to $80 from $73 at UBS
UBS analyst A.J. Rice raised his price target on Centene to $80 from $73 following the company's Q1 earnings report. Q1 results are expected to be the lowest quarter due to seasonality, with consensus skewed to the second half of the year, he noted. The company was recently awarded a Pennsylvania TANF contract which could push the company toward the higher end of the range, said Rice, who reiterated his Buy rating on Centene shares.
02/07/17
CANT
02/07/17
NO CHANGE
Target $85
CANT
Centene transferred with a Buy at Cantor
Cantor Fitzgerald analyst Steven Halper assumed coverage of Centene with a Buy rating and $85 price target.
01/03/17
PIPR
01/03/17
INITIATION
Target $67
PIPR
Centene initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Sarah James initiated Centene with an Overweight and a $67 price target.
ESRX Express Scripts
$66.06

-0.78 (-1.17%)

03/15/17
WELS
03/15/17
DOWNGRADE
WELS
Underperform
Express Scripts downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Peter Costa downgraded Express Scripts (ESRX) to Underperform saying the shares do not reflect the 20%-40% earnings risk related to re-pricing of or losing the Anthem (ANTM) contract. The analyst also sees risk of market share losses related to Express' pharmacy benefit manager model. Costa cut his price target range for the shares to $52-$56 from $79-$85.
03/09/17
CLVD
03/09/17
NO CHANGE
CLVD
Express Scripts may have lost GM contract, says Cleveland Research
Cleveland Research said Express Scripts (ESRX) may have lost the General Motors (GM) contract and will likely lose employers that are part of HTA.
03/15/17
03/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Express Scripts (ESRX) downgraded to Underperform from Market Perform at Wells Fargo with analyst Peter Costa saying the shares do not reflect the 20%-40% earnings risk related to re-pricing of or losing the Anthem (ANTM) contract. The analyst also sees risk of market share losses related to Express' pharmacy benefit manager model. Costa cut his price target range for the shares to $52-$56 from $79-$85. 2. AMC Entertainment (AMC) downgraded to Underperform from Neutral at Credit Suisse with analyst Omar Sheikh saying 2017 will be a transition year with investments likely depressing cash flow. Over the long term, the analyst believes premium video on demand could be disruptive to the business models of exhibitors. He cut his price target for AMC shares to $26 from $34. 3. American Water (AWK) downgraded to Hold from Buy at HSBC with analyst Verity Mitchell citing the recent rally in the shares and the belief that rising interest rates are likely to be less supportive of a regulated utility that yields only 2.2% for 2017. The analyst keeps a $79 price target for the shares. 4. Citrix (CTXS) downgraded to Neutral on valuation at BofA/Merrill with analyst Kash Rangan citing valuation, and raised his price target to $91 from $87. 5. Ventas (VTR) downgraded to Sell from Neutral at Goldman with analyst Andrew Rosivach saying rising interest rates will meaningfully affect the company's ability to produce external growth. The analyst cut his price target for the shares to $56 from $70. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
LEER
03/07/17
NO CHANGE
Target $75
LEER
Market Perform
Leerink 'incrementally more positive' on Express Scripts
Leerink analyst David Larsen is "incrementally more positive" on Express Scripts after speaking with management about a variety of issues. The analyst believes that under the leadership of new CEO Tim Wentworth, Express Scripts is taking a more aggressive and creative approach to the market, thinks PBMs are on the right side of the ongoing drug-pricing saga, and notes that the stock has pulled in about 25% from its 2-year highs. He reiterates a Market Perform and $75 price target on the shares.
CHRS Coherus Biosciences
$22.50

0.325 (1.47%)

12/19/16
MAXM
12/19/16
NO CHANGE
Target $43
MAXM
Buy
Drop outs of Neulasta competitors may benefit Coherus in EU, says Maxim
Maxim analyst Jason McCarthy noted that Gedeon Richter and STADA Arzneimittel AG have withdrawn their respective MAAs for biosimilar Neulasta, which he said may put Coherus Biosciences in a good position in terms of the competitive landscape for the drug in Europe. Novartis (NVS) and Mylan (MYL) had filed before Coherus and Apotex may file in 2017, noted McCarthy. In the U.S., Novartis' BLA was rejected by the FDA and Coherus could have a two-year head start in commercialization of biosimilar Neulasta, added the analyst, who has a Buy rating and $43 price target on Coherus shares.
11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.
11/25/16
STPT
11/25/16
INITIATION
Target $40
STPT
Buy
Coherus Biosciences initiated with a Buy at Standpoint Research
Target $40.
02/01/17
MAXM
02/01/17
NO CHANGE
Target $43
MAXM
Buy
Coherus focus on IP gives it leg up in biosimilar Humira race, says Maxim
After Coherus BioSciences (CHRS) announced that it has filed four petitions for Inter Partes Review seeking invalidation of AbbVie's (ABBV) U.S. patent that protects formulations of Humira that do not include a buffer, Maxim analyst Jason McCarthy said he believes Coherus' focus on IP increases the company's probability of success in being first to market in the race for biosimilar Humira. The analyst, who thinks Coherus could potentially bring a Humira biosimilar to market by as early as 2019, keeps a Buy rating and $43 price target on Coherus shares.
ONCE Spark Therapeutics
$59.50

0.59 (1.00%)

02/09/17
LEER
02/09/17
INITIATION
Target $85
LEER
Outperform
Spark Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Spark Therapeutics with an Outperform rating and $85 price target. The stock deserves a premium valuation given the company's "deep gene therapy expertise," Schwartz tells investors in a research note.
02/09/17
02/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Hold at Loop Capital. 2. Spark Therapeutics (ONCE) initiated with an Outperform at Leerink. 3. GTT Communications (GTT) initiated with a Buy at BTIG. 4. Westlake Chemical (WLK) initiated with a Buy at Citi. 5. Bio-Techne (TECH) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/16
BMOC
12/20/16
INITIATION
BMOC
Outperform
Spark Therapeutics initiated at BMO Capital
As noted earlier, BMO Capital started coverage of Spark with an Outperform rating and a $69 price target. Analyst Matthew Luchini says that approval of Spark's voretigene neparvovec for rare eye disease "could transform the treatment of rare eye disease." The analyst is also upbeat on the company's treatment for hemophilia A, its treatment for hemophilia B, and its treatment for another rare eye disease, choroidermia. Data for hemphilia A and the choroidermia treatment should be announced by the middle of 23017, according to the analyst.
12/05/16
RHCO
12/05/16
NO CHANGE
RHCO
Spark may be pressured but outlook still positive, says SunTrust
SunTrust analyst Edward Nash believes that Spark Therapeutics' stock "may be pressured" after a second patient experienced an immune response after taking its SPK-9001 drug. However, Nash says that, "both cases have been effectively managed and...neither has had a significant negative impact on the treatment benefit." He remains upbeat on SPK-9001's outlook and reiterates his $72 price target and Buy rating on the shares.
HALO Halozyme
$13.86

0.55 (4.13%)

11/03/16
DBAB
11/03/16
INITIATION
Target $12
DBAB
Buy
Halozyme initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Halozyme with a Buy rating and $12 price target.
01/05/17
PIPR
01/05/17
NO CHANGE
Target $20
PIPR
Overweight
Halozyme price target raised to $20 after pancreas cancer data at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target on Halozyme to $20 from $18, saying the company's "encouraging" Phase 2 data for its pancreas cancer combination treatment reduce the risk to the ongoing Phase 3 program for the combo. Duncan keeps an Overweight rating on Halozyme.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
09/16/16
PIPR
09/16/16
NO CHANGE
Target $18
PIPR
Overweight
Halozyme price target raised to $18 from $15 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Halozyme Therapeutics to $18 after hosting investor meetings with management. The analyst now has increased conviction in the long-term value of the company's ENHANZE products. He reiterates an Overweight rating on the shares.
UHS Universal Health
$121.47

1.42 (1.18%)

12/14/16
12/14/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to Neutral from Overweight at JPMorgan with analyst Rod Hall saying the shares are near fair value while the global consumer picture "remains negative." 2. Prudential (PRU) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Nigel Dally saying he recommends taking some profits following the post election surge. 3. Proteon Therapeutics (PRTO) downgraded to Neutral from Outperform at Baird, to Perform from Outperform at Oppenheimer, to Market Perform at JMP Securities, to Hold from Buy at Stifel, to Market Perform at Raymond James, and to Market Perform from Outperform at Cowen. 4. Universal Health (UHS) downgraded to Market Perform from Outperform at Raymond James with analyst John Ransom saying he sees increasing political risk following Senator Grassley's letter to the inspector general regarding details of the current federal investigation into Universal Health and thinks it's possible that increased political scrutiny could result in more caution and/or red tape into the admissions process, either from self-policing or externally. 5. Lincoln National (LNC) downgraded to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/17
PIPR
03/06/17
UPGRADE
Target $147
PIPR
Overweight
Universal Health upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James upgraded Universal Health Services (UHS) to Overweight saying the valuation gap between the company and industry leader HCA Holdings (HCA) is more attractive. The analyst expects the labor shortage to resolve in the second half of 2017, driving incremental EBITDA. She raised her price target for the shares to $147 from $119.
02/14/17
WOLF
02/14/17
UPGRADE
Target $142
WOLF
Outperform
Universal Health upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Universal Health to Outperform and raised its price target to $142 from $127 due to improving risk/reward, grater visibility on 2017 earnings, and expectations for uncertainty around psych business operations to dissipate overtime.
01/03/17
PIPR
01/03/17
INITIATION
Target $119
PIPR
Neutral
Universal Health initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James initiated Universal Health with a Neutral and a $119 price target..
MMSI Merit Medical

10/24/16
ADAM
10/24/16
NO CHANGE
Target $29
ADAM
Buy
Merit Medical weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills noted Merit Medical announced a DOJ investigation, which will probably lead to weakness in its shares. The analyst said the type of investigation is becoming more commonplace in the med-tech industry and more often than not leads to a an opportunity for investors to make money. Mills would be an opportunistic buyer of the shares and believes the company is set to report another solid quarter. Mills reiterated his Buy rating and $29 price target on Merit Medical shares.
02/22/17
ADAM
02/22/17
NO CHANGE
Target $35
ADAM
Buy
Merit Medical price target raised to $35 from $29 at Canaccord
Canaccord analyst Jason Mills raised his price target to $35 from $29 on Merit Medical shares following Q4 results. The analyst cited outstanding guidance, impressive gross margins, controlled operating expenses, and a continual shift toward higher gross margin products. Mills reiterated his Buy rating on Merit Medical shares.
07/28/16
BRRR
07/28/16
DOWNGRADE
BRRR
Market Perform
Merit Medical downgraded to Market Perform from Outperform at Barrington
07/28/16
BRRR
07/28/16
DOWNGRADE
BRRR
Market Perform
Merit Medical downgraded to Market Perform at Barrington
As previously reported, Barrington analyst Michael Petusky downgraded Merit Medical to Market Perform from Outperform, citing his view that near-term price appreciation will be limited following the stock's 50% rally from its February lows.
NK NantKwest
$3.81

0.25 (7.02%)

01/24/17
JEFF
01/24/17
DOWNGRADE
Target $6
JEFF
Hold
NantKwest downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded NantKwest to Hold and cut his price target for the shares to $6 from $30. The analyst views the shares as fairly valued given a lack of meaningful catalysts over the next 12-18 months. He cites "increased risks, delayed timelines and reprioritization of certain programs" for the new price target.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
NantKwest initiated with a Market Perform at Raymond James
DXCM Dexcom
$77.21

-0.26 (-0.34%)

01/20/17
SPHN
01/20/17
NO CHANGE
Target $95
SPHN
Overweight
Dexcom price target raised to $95 from $75 at Stephens
Stephens analyst Chris Cooley raised his price target for Dexcom to $95 from $75 on valuation. The analyst believes the company's recent reimbursement win serves to bolster his optimism that corporate annual revenue guidance may ultimately prove conservative. He reiterates an Overweight rating on the shares.
03/01/17
LEER
03/01/17
NO CHANGE
Target $90
LEER
Outperform
Dexcom price target raised to $90 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Dexcom to $90 from $80 following Q4 results. At the very least, the analyst believes recently-announced CMS coverage makes Dexcom's 2017 sales growth guidance easily achievable, and at best likely beatable. And with a plethora of incremental growth drivers, the company is well-positioned to drive "sustainable strong" double-digit growth longer term, she adds. Antalffy reiterates an Outperform rating on the shares.
02/27/17
WEDB
02/27/17
NO CHANGE
WEDB
Outperform
Dexcom info on prior recall could create 'temporary disruption,' says Wedbush
Wedbush analyst Tao Levy noted that the Swiss Agency for Therapeutic Products announced that Dexcom is recalling and offering to replace all G4 Platinum and G5 Mobile Receivers in Switzerland shipped prior to September 23, 2016 and he would not be surprised to see similar notifications in other countries where Dexcom's products are sold. A charge related to recalls could amount to $36M at the "upper end," but would likely be lower, estimates Levy, who adds that while the recall may cause some "temporary disruption," it should also put this issue to rest. The firm has an Outperform rating on Dexcom shares.
01/17/17
OPCO
01/17/17
NO CHANGE
Target $98
OPCO
Outperform
Dexcom price target raised to $98 from $84 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Dexcom to $98 from $84 on increased medium/long-term Medicare estimates. The analyst believes the Centers for Medicare and Medicaid Services' decision to approve coverage of the company's G5 CGM opens up a new market for Dexcom, and says he continues to view 2017 sales guidance as conservative. Further, Lichtman continues to see several offsets to competition, and notes that "big new launches" remain on track for 2018. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CCN

CardConnect

$13.65

-0.25 (-1.80%)

, FDC

First Data

$16.64

-0.03 (-0.18%)

20:43
05/29/17
05/29
20:43
05/29/17
20:43
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

CCN

CardConnect

$13.65

-0.25 (-1.80%)

FDC

First Data

$16.64

-0.03 (-0.18%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

PPG

PPG

$107.24

0.33 (0.31%)

GM

General Motors

$33.07

0.47 (1.44%)

DIS

Disney

$108.41

1.14 (1.06%)

VIA

Viacom

VIAB

Viacom

$35.13

0.21 (0.60%)

F

Ford

$10.93

0.07 (0.64%)

IP

International Paper

$52.42

0.26 (0.50%)

CROX

Crocs

$6.59

0.12 (1.85%)

YHOO

Yahoo

$50.67

0.07 (0.14%)

FL

Foot Locker

$59.82

0.16 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 01

    Jun

  • 06

    Jun

  • 08

    Jun

  • 12

    Jun

  • 15

    Jun

  • 27

    Jul

  • 25

    Oct

AMGP

Antero Midstream GP

$21.97

-0.09 (-0.41%)

20:34
05/29/17
05/29
20:34
05/29/17
20:34
Initiation
Antero Midstream GP initiated  »

Antero Midstream GP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AM

Antero Midstream

$34.28

-0.06 (-0.17%)

20:32
05/29/17
05/29
20:32
05/29/17
20:32
Initiation
Antero Midstream initiated  »

Antero Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

20:30
05/29/17
05/29
20:30
05/29/17
20:30
Downgrade
Archrock Partners LP rating change  »

Archrock Partners LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGP

Antero Midstream

$21.97

-0.09 (-0.41%)

20:28
05/29/17
05/29
20:28
05/29/17
20:28
Initiation
Antero Midstream initiated  »

Antero Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$61.00

0.29 (0.48%)

20:27
05/29/17
05/29
20:27
05/29/17
20:27
Initiation
Occidental Petroleum initiated  »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRO

Frontline

$5.63

-0.39 (-6.48%)

, AMWD

American Woodmark

$88.90

1.3 (1.48%)

20:25
05/29/17
05/29
20:25
05/29/17
20:25
Earnings
Notable companies reporting before Tuesday's open »

Notable companies…

FRO

Frontline

$5.63

-0.39 (-6.48%)

AMWD

American Woodmark

$88.90

1.3 (1.48%)

SFL

Ship Finance

$13.05

-0.25 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

WDC

Western Digital

$90.01

0.74 (0.83%)

, TOSBF

Toshiba, also use TOSYY

$2.30

0.0023 (0.10%)

20:04
05/29/17
05/29
20:04
05/29/17
20:04
Periodicals
INCJ considers joint bid with Western Digital for Toshiba chips, Nikkei says »

State-backed Innovation…

WDC

Western Digital

$90.01

0.74 (0.83%)

TOSBF

Toshiba, also use TOSYY

$2.30

0.0023 (0.10%)

TOSYY

Toshiba, also use TOSBF

$13.80

-0.1 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$971.47

1.93 (0.20%)

, GOOGL

Alphabet Class A

$993.27

1.41 (0.14%)

20:01
05/29/17
05/29
20:01
05/29/17
20:01
Periodicals
Google, Sharp partner on VR displays, Nikkei says »

Google (GOOG) and…

GOOG

Alphabet

$971.47

1.93 (0.20%)

GOOGL

Alphabet Class A

$993.27

1.41 (0.14%)

HNHPF

Hon Hai Precision

SHCAY

Sharp

$3.80

0.1 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 28

    Jun

  • 19

    Jul

MU

Micron

$29.76

0.33 (1.12%)

19:58
05/29/17
05/29
19:58
05/29/17
19:58
Periodicals
Micron to invest $2B in Japan memory chip facility, Nikkei says »

Micron plans to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 09

    Jun

  • 15

    Jun

LNEGY

Linde

$19.28

-0.09 (-0.46%)

19:56
05/29/17
05/29
19:56
05/29/17
19:56
Periodicals
Linde to receive 'major' order from Russian company, Reuters says »

Linde is set to receive a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.64

-0.03 (-0.18%)

, CCN

CardConnect

$13.65

-0.25 (-1.80%)

19:38
05/29/17
05/29
19:38
05/29/17
19:38
Hot Stocks
First Data to acquire CardConnect for $15.00 per share »

First Data (FDC) and…

FDC

First Data

$16.64

-0.03 (-0.18%)

CCN

CardConnect

$13.65

-0.25 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

SSNLF

Samsung

$2,000.00

200 (11.11%)

, LYV

Live Nation

$34.25

0.05 (0.15%)

19:33
05/29/17
05/29
19:33
05/29/17
19:33
Hot Stocks
Samsung announces 'VR Live Pass,' new virtual reality partnerships »

Samsung (SSNLF) announced…

SSNLF

Samsung

$2,000.00

200 (11.11%)

LYV

Live Nation

$34.25

0.05 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

FISV

Fiserv

$124.09

-0.43 (-0.35%)

19:31
05/29/17
05/29
19:31
05/29/17
19:31
Hot Stocks
Fiserv says selected by Bank of Sydney »

Fiserv announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$37.55

1.6 (4.45%)

19:29
05/29/17
05/29
19:29
05/29/17
19:29
Periodicals
Nintendo orders production ramp for 'Switch' console, FT reports »

Nintendo has ordered a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$325.14

8.31 (2.62%)

, CSIQ

Canadian Solar

$13.24

-0.48 (-3.50%)

19:16
05/29/17
05/29
19:16
05/29/17
19:16
Hot Stocks
WTO says U.S. launches investigation into solar cell imports »

The World Trade…

TSLA

Tesla

$325.14

8.31 (2.62%)

CSIQ

Canadian Solar

$13.24

-0.48 (-3.50%)

FSLR

First Solar

$36.84

-1.1 (-2.90%)

JASO

JA Solar

$6.91

-0.28 (-3.89%)

SPWR

SunPower

$7.95

-0.28 (-3.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 06

    Jun

  • 20

    Jun

  • 29

    Jun

  • 02

    Oct

LRLCY

L'Oreal

$42.24

-0.165 (-0.39%)

18:47
05/29/17
05/29
18:47
05/29/17
18:47
Periodicals
Renhe Pharmacy mulls joining auction for The Body Shop, Sky News says »

China's Renhe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$153.61

-0.26 (-0.17%)

, QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

18:43
05/29/17
05/29
18:43
05/29/17
18:43
Periodicals
Apple hires former Qualcomm VP to head SoC efforts, AppleInsider says »

Apple (AAPL) has hired…

AAPL

Apple

$153.61

-0.26 (-0.17%)

QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

GS

Goldman Sachs

$223.53

1.06 (0.48%)

18:40
05/29/17
05/29
18:40
05/29/17
18:40
Periodicals
Goldman Sachs bought $2.8B in Venezuelan bonds, WSJ says »

Goldman Sachs purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 18

    Jul

  • 17

    Oct

ICAGY

IAG

$15.65

-0.305 (-1.91%)

18:36
05/29/17
05/29
18:36
05/29/17
18:36
Hot Stocks
British Airways suffers 'major' IT failure »

IAG's British…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.01

-0.47 (-0.61%)

18:20
05/29/17
05/29
18:20
05/29/17
18:20
Hot Stocks
Canadian National reaches tentative labor with train conductors, yard employees »

CN announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:29
05/29/17
05/29
16:29
05/29/17
16:29
Hot Stocks
PPG says remains willing to engage with AkzoNobel »

PPG (PPG) issued the…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:27
05/29/17
05/29
16:27
05/29/17
16:27
Periodicals
Court rejects Elliott challenge against AkzoNobel, Bloomberg says »

The Dutch Commercial…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$108.41

1.14 (1.06%)

, VIA

Viacom

16:21
05/29/17
05/29
16:21
05/29/17
16:21
Hot Stocks
Box Office Battle: 'Pirates' wins holiday weekend as 'Baywatch' stumbles »

Disney's (DIS)…

DIS

Disney

$108.41

1.14 (1.06%)

VIA

Viacom

VIAB

Viacom

$35.13

0.21 (0.60%)

FOX

21st Century Fox

$26.95

-0.28 (-1.03%)

FOXA

21st Century Fox

$27.03

-0.3 (-1.10%)

TWX

Time Warner

$99.07

0.1025 (0.10%)

CMCSA

Comcast

$40.91

0.57 (1.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$27.76

2.21 (8.65%)

LGF.B

Lionsgate

$25.56

2.11 (9.00%)

SNE

Sony

$36.68

0.51 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 12

    Jun

  • 15

    Jun

  • 15

    Jun

  • 27

    Jun

DGAS

Delta Natural Gas

15:56
05/29/17
05/29
15:56
05/29/17
15:56
Conference/Events
Delta Natural Gas to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.